5-Amino-1MQ Safety: What Is Known and What Is Not
5-amino-1-methylquinolinium, usually shortened to 5-amino-1MQ, is a small molecule inhibitor of NNMT. It is not a peptide, despite showing up in the same online marketplaces as peptides like BPC-157 or retatrutide. It has no FDA-approved indication for any human use, is not listed on the FDA's 503A bulk drug substances list, and cannot legally be compounded for patients under that pathway. For a fuller regulatory picture, see the 5-amino-1MQ FDA status page and the FDA Peptide Status Tracker.
What has actually been tested in a living organism?
Almost nothing, and only in rodents. A 2021 pharmacokinetic study developed an LC-MS/MS assay to measure 5-amino-1MQ in rat plasma and reported oral bioavailability data in that species (Paletta et al., 2021). That paper tells you the compound is absorbed after oral dosing in rats and gives pharmacokinetic parameters in rats. It does not establish a safe or effective dose in humans, and rat-to-human extrapolation for a compound with no clinical trial history is not something a reader should do on their own.
Separately, a mouse study found that a selective, membrane-permeable NNMT inhibitor reversed several features of high-fat-diet-induced obesity, including reduced body weight gain and improved metabolic markers, in mice fed a high-fat diet (Neelakantan et al., 2018). This is genuine evidence that NNMT inhibition changes metabolism in an obese mouse model. It is not evidence that 5-amino-1MQ is safe, or effective, in humans. No published human trial of 5-amino-1MQ, at any dose, exists in the literature reviewed for this page.
Why would inhibiting NNMT raise any safety questions at all?
NNMT sits at a metabolic crossroads. It methylates nicotinamide using S-adenosylmethionine as the methyl donor, producing N1-methylnicotinamide and consuming methyl groups that would otherwise be available for other methylation reactions in the cell (Ulanovskaya et al., 2013 assay work continued in Neelakantan 2016; mechanistic review, Pissios lab, 2021). NNMT also influences nicotinamide availability, which is a precursor in NAD+ salvage metabolism, and NNMT expression changes with glucose availability in adipocytes (Riederer et al., 2020).
That dual role, methyl group consumption plus a link to NAD+ precursor pools, is exactly why NNMT is being pursued as a drug target for obesity and type 2 diabetes (Kannt & Wohlfart, 2021; 2024 review) and why blocking it is not automatically risk-free. If NNMT inhibition shifts methyl group availability or NAD+ precursor handling in ways that differ by tissue, that is a plausible mechanism for off-target effects that has not been characterized in humans at all. This is a theoretical concern raised by the biology, not a documented adverse effect, and readers should not treat it as a confirmed risk. It should also not be dismissed, because nobody has looked for it in a person.
NNMT also shows up in oncology research: it has been studied for a role in modulating drug response in cancer cells via RNA methylation pathways (Yang et al., 2023) and antiproliferative effects have been observed with NNMT inhibitors in cervical cancer cell lines (2021 in vitro study). These are cell-culture findings relevant to drug discovery, not evidence about cancer risk or benefit from taking 5-amino-1MQ. They illustrate that NNMT has effects well outside metabolism, which is another reason broad claims of "it just helps you lose fat" oversimplify the biology.
What symptoms have people reported, and how much does that count as evidence?
Because there is no published human trial, there is no systematic adverse event data of any kind, positive or negative. Anecdotal reports circulating in online forums and marketing material are not verifiable, are not controlled for dose, purity, or co-exposures, and cannot be cited as safety evidence on a medical page. If a source you're reading cites "user reports" of mild or absent side effects as reassurance, that is marketing framing, not clinical evidence. The correct clinical statement is that the safety profile in humans is unestablished, full stop.
Does sourcing quality change the risk profile?
Yes, independent of anything NNMT does biologically. Because 5-amino-1MQ has no FDA-approved manufacturing pathway and is not on the 503A bulks list, product sold as "5-amino-1MQ" is not subject to pharmaceutical manufacturing standards, potency verification, or sterility requirements. Contamination, mislabeled concentration, and substitution with an entirely different compound are documented risks across the unregulated research-chemical market generally. That sourcing risk exists on top of, not instead of, the unknown pharmacological safety profile. See how people are sourcing 5-amino-1MQ and cost factors for more on that market.
What does this mean if you are already taking it, or considering it?
A three-tier way to think about any claim you encounter about 5-amino-1MQ:
| Claim type | Example | What it actually supports |
|---|---|---|
| Enzyme/in vitro evidence | "5-amino-1MQ inhibits NNMT selectively" | Supports mechanism of action; says nothing about clinical effect or safety in a person |
| Animal evidence | "Reversed obesity markers in high-fat-diet mice" | Supports biological plausibility in a specific model; does not establish human dose, efficacy, or safety |
| Human evidence | (none published) | This tier does not exist yet for 5-amino-1MQ. Any specific human dosing, duration, or safety claim you see online is not backed by a trial |
If a claim you're reading cites a source, check which tier it belongs to before deciding how much weight to give it. Most marketing claims about 5-amino-1MQ quietly borrow authority from tier 1 or tier 2 studies while implying tier 3 conclusions.
Practical points that follow from the evidence gaps:
- There is no verified safe dose range in humans. Any specific milligram number you see quoted online is not derived from a human trial; see the dosing claims page for why those numbers should not be treated as clinical guidance.
- Anyone with liver disease, kidney disease, a methylation-related condition, or on medications that affect methyl donor metabolism should treat NNMT inhibition as an unknown variable and discuss it with a clinician before use, since the relevant human interaction data does not exist to rule concerns in or out.
- Pregnancy, breastfeeding, and use in anyone under 18 should be considered contraindicated in practice, in the absence of any human safety data at all.
- Stop use and seek medical care for any new or worsening symptoms after starting an unregulated compound, particularly signs suggestive of liver involvement (jaundice, dark urine, right upper quadrant pain) or unexplained systemic symptoms. This is standard caution for any unregulated substance, not a specific finding about 5-amino-1MQ.
What would change this picture?
A registered human clinical trial with a defined dose, a monitored safety endpoint, and published results would be the first real safety evidence for this compound in people. Until that exists, the accurate answer to "is 5-amino-1MQ safe" is that safety has not been established, not that it has been established as safe or as dangerous. For the broader efficacy question, see the weight-loss evidence page and how 5-amino-1MQ compares to GLP-1 medications, both of which run into the same evidence ceiling described here.
Evidence boundary: established are the in vitro NNMT inhibition mechanism and the rodent metabolic and pharmacokinetic findings cited above. Plausible but unproven is that these mechanisms translate to meaningful fat loss or metabolic benefit in humans at a tolerable dose. Not established, at all, is human safety, human efficacy, or a verified human dose. Readers should weigh any product claim against that gap, not against the mouse data alone.